Mammalian target of rapamycin (mTOR) plays a crucial role in the control of T cell fate determination; however, the precise regulatory mechanism of the mTOR pathway is not fully understood. We found that T cell-specific deletion of the gene encoding tuberous sclerosis 1 (TSC1), an upstream negative regulator of mTOR, resulted in augmented Th1 and Th17 differentiation and led to severe intestinal inflammation in a colitis model. Conditional Tsc1 deletion in Tregs impaired their suppressive activity and expression of the Treg marker Foxp3 and resulted in increased IL-17 production under inflammatory conditions. A fate-mapping study revealed that Tsc1-null Tregs that lost Foxp3 expression gained a stronger effector-like phenotype compared with Tsc1 -/-Foxp3 + Tregs. Elevated IL-17 production in Tsc1 -/-Treg cells was reversed by in vivo knockdown of the mTOR target S6K1. Moreover, IL-17 production was enhanced by Treg-specific double deletion of Tsc1 and Foxo3a. Collectively, these studies suggest that TSC1 acts as an important checkpoint for maintaining immune homeostasis by regulating cell fate determination.
Introduction
Mammalian target of rapamycin (mTOR), a conserved Ser/Thr protein kinase, functions as a sensor of the cellular nutrient and energy status and regulates metabolism, protein synthesis, and proliferation (1, 2) . It exists in two forms, either mTOR complex 1 (mTORC1) or complex 2 (mTORC2), which are characterized by their assembly with different signaling proteins (3) . Recent studies have revealed that the mTOR signaling pathway is crucially involved in the process of T cell fate determination, including the differentiation of naive cells into either effector or regulatory T (Treg) cells and the development of CD8 memory T cells (4) (5) (6) (7) (8) . Genetic ablation of mTOR in mice results in the failed differentiation of T helper (Th) 1, 2, and 17 cells, whereas mTOR-deficient T cells become Foxp3 + Treg cells when activated (9) . The important role of mTOR in regulating Foxp3 + Treg cell responsiveness or stability has been implicated by studies of the mTOR inhibitor rapamycin (10, 11) . More recent studies of Rheb-or Rictor-deficient mice suggest that distinct mTORC1 or mTORC2 activities selectively regulate each subset of effector T cells, but inhibition of both activities is required for the spontaneous generation of Foxp3 + Treg cells (6) . Despite all these findings, regulation of the mTOR pathways in Th/Treg differentiation and the underlying immune responses are still not fully understood.
Tuberous sclerosis complex 1 (TSC1 or hamartin), which forms a heterodimeric complex with TSC2 (tuberin), inhibits mTORC1 by promoting the conversion of guanosine triphosphate (GTP) into guanosine diphosphate (GDP) on the mTORC1 activator Rheb. Genetic deletion of TSC1 or TSC2 causes constitutive activation of mTORC1 signaling, leading to the attenuation of PI3K signaling (12) . The important function of TSC1 in T cell activation and homeostasis was recently demonstrated by an analysis of mice with TSC1-deleted T cells (13) (14) (15) (16) (17) ; hyperactivation of mTORC1 in these TSC1-deficient T cells resulted in a survival defect, loss of quiescence, and resistance to T cell anergy, which disrupted T cell homeostasis. However, the influence of TSC1 on the interplay between Th and Treg cell responses, particularly under inflammatory conditions, still remains unknown.
Several studies have suggested that Treg cells exhibit phenotypic and functional plasticity that allows them to reprogram into effector-type T cells that can adapt to microenvironmental changes (18) (19) (20) (21) . To trace the fates of Foxp3 + Treg cells in vivo, Zhou et al. generated double-transgenic reporter mice to demonstrate that Treg cells can lose Foxp3 expression to become Foxp3-negative "ex-Treg" cells and acquire an effector or memory cell phenotype under autoimmune conditions (22) . However, another study provided evidence that Treg cells are stable under various inflammatory conditions (23) . It was more recently suggested that the committed Treg cells sustain Foxp3 expression and refrain from reprogramming, whereas only uncommitted Treg cells could convert into "ex-Treg" cells (24) . Obviously, the regulatory mechanism for determining the stability and maintenance of Treg cells remains to be addressed.
To address these issues, we generated mice with a conditional deletion of TSC1 in either T cells or Treg cells, together with a fate-mapping approach, and we studied the role of TSC1 in modulating Th17 and Treg cell responses under normal and inflammatory conditions. Our results suggest an essential role of TSC1 in modulating Th cell differentiation and Treg cell conversion and stability in response to environmental cues via the regulation of both mTORC1 and mTORC2 signaling pathways.
Results

TSC1 is required to maintain mucosal immune homeostasis.
In order to more precisely understand how the mTOR pathway is involved in the regulation of CD4 + T cell responses, we bred mice carrying a loxP-flanked Tsc1 allele with mice expressing Cre recombinase from the CD4 promoter to delete TSC1 specifically in T lymphocytes (referred to herein as Cd4 Cre Tsc1 f/f mice). Since it has been reported that TSC1 deficiency in T cells results in enhanced T cell activation (15, 17), we monitored WT and Cd4 Cre Tsc1 f/f mice over 20 weeks of age for clinical signs of autoimmunity. Histological staining of colon and liver sections revealed that Cd4 Cre Tsc1 f/f mice, but not WT mice, spontaneously developed inflammation characterized by lymphocyte infiltration and large lymphoid aggregates ( Figure 1A) .
Because effector T cells of the adaptive immune system may play a role in sustaining rather than initiating intestinal inflammation, which in many cases is driven by the innate immune system (25), we used a dextran sodium sulfate-induced (DSS-induced) model of chronic colitis to assess the progression from the acute to the chronic phase in Cd4 Cre Tsc1 f/f mice. We exposed the WT and Cd4 Cre Tsc1 f/f mice to 2% DSS in the drinking water for 7 days and analyzed them up to 4 weeks after DSS removal ( Figure 1B) . We recorded body weight loss during the DSS treatment and recovery period. Cd4 Cre Tsc1 f/f mice showed a relatively rapid and more severe weight loss. Also, the recovery from weight loss in Cd4 Cre Tsc1 f/f mice was much slower after DSS removal compared with that in WT mice ( Figure 1C ). On day 28, we observed colon length shortening ( Figure 1D ) and a substantial increase in the size of the spleen and mesenteric lymph nodes (MLNs) ( Figure 1E ) in Cd4 Cre Tsc1 f/f mice compared with that found in WT mice. Cd4 Cre Tsc1 f/f mice also displayed more severe lymphocytic infiltration and destruction of epithelial architecture in the colon on day 28 ( Figure 1F ) and even up to day 35 (Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI69751DS1). Collectively, these results suggest that TSC1 deficiency in CD4 + effector T cells leads to an increased susceptibility to intestinal inflammation.
We next examined the production of proinflammatory cytokines by CD4 + T cells in the colon and spleen of DSS-treated mice. On day 28, there was a significant increase in IFN-γ and IL-17A production by TSC1-deficient CD4 + T cells ( Figure 1G ), and this increase was sustained until day 35 (Supplemental Figure 1B) . There was no appreciable difference, however, between WT and Cd4 Cre Tsc1 f/f mice under both basal and acute colitis conditions with 3% DSS (Supplemental Figure 2) . Taken together, we demonstrate a crucial role for TSC1 in restricting a proinflammatory T cell response that prevented the development of chronic intestinal inflammation and maintained intestinal homeostasis.
TSC1 restricts Th1 and Th17 cell differentiation. We cultured WT and TSC1-deficient naive CD4 + T cells under polarizing conditions for Th1 or Th17 cell differentiation, including coincubation with appropriate cytokines and anticytokine antibodies for 5 days, followed by restimulation with anti-CD3 and anti-CD28. Intracellular cytokine staining for IFN-γ and IL-4 or IL-17A showed that cytokine production from the Th1 and Th17 subsets was substantially increased under polarizing conditions in TSC1-deficient T cells (Figure 2A ). This increase was further confirmed by measuring cytokine secretion by ELISA, with concentrations of signature cytokines for Th1 and Th17 responses being markedly increased in the culture supernatants of TSC1-deficient T cells ( Figure 2B ). Consistently, TSC1-deficient T cells exhibited significantly elevated mRNA levels of Tbx21 and Rorc under Th1-and Th17-polarizing conditions, respectively ( Figure 2C ). These results indicate that TSC1 is required for the limitation of Th cell differentiation in vitro.
To investigate the biological relevance of TSC1 in Th cell responses, we examined the effect of TSC1 deficiency on the generation of Th1 and Th17 subsets using in vivo mouse models. We adoptively transferred CD4 + T cells from WT or Cd4 Cre Tsc1 f/f OVA-specific OT-II transgenic mice into CD45.1 congenic C57BL/6 mice and then immunized them with an OVA peptide plus CFA as an adjuvant. We found that OVA-induced IFN-γ-producing Th1 cells were greatly increased in the mice receiving TSC1-deficient OT-II T cells ( Figure 2D, upper panel) . Likewise, TSC1 deficiency resulted in an increased IL-17-producing T cell population ( Figure 2D, lower panel) .
A previous study showed that TSC1-deficient T cells have a survival defect that leads to the loss of adoptively transferred cells in recipient mice (15) . To rule out the viability issue of the transferred TSC1-deficient T cells in recipient mice, we immunized WT and Cd4 Cre Tsc1 f/f mice with keyhole limpet hemocyanin (KLH) emulsified in CFA. CD4 + T cells from the immunized mice were restimulated in vitro with KLH for 72 hours and examined the supernatants with a Bio-Plex multicytokine assay. Consistent with the adoptive transfer data, we observed an augmented induction of both Th1 and Th17 signature cytokine levels as well as IL-6 in TSC1-deficient CD4 + T cells ( Figure 2E ), suggesting that TSC1 is an important negative regulator in the generation of Th1 and Th17 cells.
TSC1 deficiency affects the ability of Treg cells to suppress colitis. The increased spontaneous inflammation likely reflected increased effector cell generation, although decreased Treg activity also could have contributed. We therefore examined the effect of TSC1 deficiency on Foxp3 expression induced by TGF-β in cultures that generate adaptive or inducible Treg (iTreg) cells. Sorted CD4 + CD62L + CD25 -naive T cells were cultured with anti-CD3 plus anti-CD28 and TGF-β for 4 days and then analyzed by intracellular staining for Foxp3. The induction of Foxp3 expression by TGF-β was similar between WT and TSC1-deficient naive CD4 + T cells ( Figure 3A) . In a coculture assay to measure suppressive activity, we found that iTreg cells from either WT or Cd4 Cre Tsc1 f/f mice effectively inhibited naive CD4 + T cell division ( Figure 3B ), which indicated that TSC1 is not required for the in vitro differentiation and suppressive function of iTreg cells triggered by TGF-β.
Although the generation and function of TSC1-deficient iTreg cells were intact in vitro, we reasoned that the breakdown of intestinal immune homeostasis in Cd4 Cre Tsc1 f/f mice may be caused not only by increased production of proinflammatory effector cytokines, but also by impaired Treg cell homeostasis or function under inflammatory conditions. Indeed, Cd4 Cre Tsc1 f/f mice with chronic DSS-induced colitis (day 28) displayed a decrease in the percentage of Foxp3 + Treg cells in the spleen compared with that observed in WT mice, and this difference was even more pronounced in colonic lamina propria (cLP) (Supplemental Figure 3) . To further investigate whether TSC1 deficiency in Treg cells is associated with the development of colitis, we cotransferred sorted CD4 + CD45RB hi (CD45.1 + ) naive T cells with or without sorted CD4 + CD45RB lo CD25 + (CD45.2 + ) Treg cells from either WT or Cd4 Cre Tsc1 f/f mice into Rag1 -/-mice and recorded their body weight changes for over a 12-week period. Rag1 -/-mice that received TSC1-deficient Treg cells gained weight until 6 weeks after transfer, but then started to lose weight and finally lost around 10% of their body weight at 12 weeks ( Figure 3C ). Consistent with the weight loss, the recipient mice that were either transferred with CD4 + CD45RB hi T cells alone or cotransferred with TSC1-deficient CD4 + CD45RB lo CD25 + Treg cells developed inflammation with enlargement of the spleen and MLNs (data not shown) and colitis with histological features of intestinal disease ( Figure 3D ). By contrast, the recipient mice that were given WT CD4 + CD45RB lo CD25 + Treg cells were resistant to the develop- Error bars indicate the mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed, unpaired Student's t test. ment of colitis. These results imply that TSC1 expression by Treg cells is required for the suppression of T cell-induced colitis.
We next analyzed the suppressive activity of transferred Treg cells by analyzing the in vivo expansion of CD4 + CD45RB hi T cells and Treg cells in Rag1 -/-recipient mice 12 weeks after transfer. In all organs analyzed, the ratio of CD4 + CD45RB hi T cells (CD45.1 + )/CD4 + CD45RB lo CD25 + Treg (CD45.2 + ) cells was increased in the recipient mice given TSC1-deficient Treg cells compared with those that received WT Treg cells ( Figure 3E ). Despite the increased ratio of naive T cells/Treg cells, the total numbers of TSC1-deficient Treg cells were similar to WT Treg cell numbers in most organs analyzed except in colon ( Figure 3F ), which suggests that the defect in colitis suppression by the transfer of TSC1-deficient Treg cells is not simply a quantitative one related to the increased ratio of effectors/Tregs, but could also be a consequence of the attenuated suppressive activity of TSC1-deficient Treg cells. Indeed, while over 97% of FACS-sorted CD4 + CD45RB lo CD25 + Treg cells were Foxp3 positive before the adoptive transfer ( Figure 3G ), we found the population that lost Foxp3 expression in the recipient mice given TSC1-deficient Treg cells 12 weeks after transfer ( Figure 3H ), which suggests a possible role of TSC1 in Treg cell regulation.
Treg-specific TSC1 deletion leads to impaired function under inflammatory conditions. To more precisely assess the intrinsic role of TSC1 in the function of Foxp3 + Treg cells, we bred Tsc1 f/f mice with Foxp3 Cre mice expressing a yellow fluorescent protein-Cre (YFP-Cre) recombinase fusion protein under the control of the Foxp3 promoter in order to delete TSC1 specifically in Foxp3 + Treg cells (referred to herein as Foxp3 YFPCre Tsc1 f/f ). TSC1 deficiency in Treg cells had no effect on the development of CD4 or CD8 single-or CD4/CD8 double-positive T cells in the thymus (Supplemental Figure 4A) . Despite slightly lower frequencies of CD4 + or CD8 + T cells in peripheral lymphoid tissues such as those found in the spleen of Foxp3 YFPCre Tsc1 f/f mice (Supplemental Figure 4 , B and C), the absolute numbers of T cells were instead slightly increased, which reflects the expanded population of non-T cells (Supplemental Figure  4D ). More importantly, the frequencies of naive (CD44 lo CD62L hi ) and effector/memory (CD44 hi CD62L lo ) CD4 + T cells were similar in Foxp3 YFPCre Tsc1 +/+ and Foxp3 YFPCre Tsc1 f/f mice (Supplemental Figure 4, E and F). These data imply that TSC1 deficiency in Treg cells did not affect T cell differentiation or homeostasis.
We then examined the effect of TSC1 deficiency on Treg cell homeostasis. CD4 + YFP + Treg cell frequencies were decreased in both the spleen and cLP of Foxp3 YFPCre Tsc1 f/f mice ( Figure 4A) , however, the total numbers of YFP + Treg cells were quite similar between the control and Foxp3 YFPCre Tsc1 f/f mice ( Figure 4B ). Although analysis of the surface markers of TSC1-deficient YFP + Treg cells displayed no alteration in the phenotype or activation status of Treg cells (Supplemental Figure 5) , we found that TSC1-deficient Treg cells exhibited a high proliferative response in vitro, as reflected in the increased expression of Ki67 ( Figure 4C , upper panel). Furthermore, TSC1-deficient Treg cells were more resistant to cell death than WT Treg cells, as assessed by 7-AAD staining 72 hours after culture with anti-CD3 and anti-CD28 ( Figure 4C, lower panel) .
Next, we examined the in vivo suppressive function of TSC1-deficient Treg cells by adoptive transfer into Rag1 -/-mice of sorted CD4 + CD45RB lo YFP + (CD45. Figure 5D , left panel). As a negative control, we measured cytokine production in CD4 + RFP -YFP -(naive) T cells sorted from Foxp3 YFPCre R26 RFP Tsc +/+ or Foxp3 YFPCre R26 RFP Tsc1 f/f mice that have intact TSC1 expression and found that cytokine production was similar between the two strains of mice ( Figure 5E ). We further confirmed the conversion of the population of TSC1-deficient Foxp3 + Treg cells into Th17-like T cells by using an in vitro conversion assay. The secretion of IL-17 from TSC1-deficient YFP + Treg cells was profoundly upregulated by in vitro culture with IL-6 and TGF-β ( Figure 5F ). In addition, TSC1-deficient RFP + YFP + Treg cells, when adoptively transferred into Rag1 -/-mice, displayed a substantial loss of Foxp3 expression ( Figure 5G ) and an increased IL-17-producing fraction in both RFP + YFP + and RFP + YFP -populations, although a profound increase in the IFN-γ-producing fraction was found only in RFP + YFP -(ex-Treg) T cells ( Figure 5H ). Overall, these data indicate that TSC1 plays an important role in preventing Treg reprogramming into Th17-like effector T cells. Figure 6C ). Furthermore, to see the effect of TSC1 deletion on Treg cell integrity, we monitored 7-month-old Foxp3 YFPCre R26 RFP Tsc1 f/f mice. These older mice exhibited increases in an effector/memory phenotype (Supplemental Figure 6B ) and modest increases in lymphoid aggregates and infiltration in colon (data not shown), together with an elevated population of RFP + YFP -(ex-Treg) Treg cells (Supplemental Figure 6A) . Collectively, these data reinforce the importance of TSC1 in retaining Treg cell identity and immune homeostasis.
TSC1 deficiency promotes the acquisition of a Th17-like effector phenotype in Treg cells in an intrinsic manner. Since Treg cells in lymp-
S6K1 is involved in IL-17 production in TSC1-deficient T cells.
To understand the molecular mechanisms by which TSC1 regulates Th17 response, we examined the downstream signaling events in TSC1-deficient T cells. Consistent with a previous study (15) , phosphorylation of the mTORC1 substrate S6K1 was increased in TSC1-deficient T cells upon TCR/CD28 stimulation, whereas phosphorylation of mTORC2 downstream substrates Foxo1 and Foxo3a was reduced ( Figure 7A ). We found that the expression level of GRB10, which was recently identified as a target of mTORC1 (27, 28) , was increased. To examine whether these mTORC1 targets are functionally involved in altered Th17 differentiation of TSC1-deficient T cells, we performed retrovirus-based knockdown of S6K1 or GRB10 expression by synthesizing small hairpin RNAs that were constructed into the murine stem cell virusbased (MSCV-based) pLMP-GFP retroviral vector. We selected the probe with the highest knockdown efficiency by validation in mouse primary T cells (data not shown) and retrovirally transduced it into mouse bone marrow cells from WT or CD4 cre Tsc1 f/f mice. Then, S6K1 shRNA-or GRB10 shRNA-expressing chimeric mice were generated by bone marrow transplantation into lethally irradiated CD45.1 congenic B6 recipient mice. Eight weeks after reconstitution, newly reconstituted CD4 + T cells (CD45.2 + GFP + ) expressing either control or S6K1 or GRB10 shRNA were sorted from the spleen of bone marrow chimeric mice ( Figure 7B , upper panel), and the efficient reduction of S6K1 or GRB10 expression was verified by immunoblotting in the shRNA-expressing CD4 + T cells ( Figure 7B, lower panel) . When sorted naive CD4 + T cells were cultured under polarizing conditions for Th17 differentiation, S6K1 shRNA-expressing WT T cells displayed reduced Th17 differentiation. Importantly, S6K1 knockdown in TSC1-deficient T cells markedly reduced the differentiation of naive T cells into a Th17 subset ( Figure 7C ). The level of IL-17 was also significantly decreased in the culture supernatants of S6K1 shRNA-expressing TSC1-deficient T cells ( Figure 7D) . However, the effect of GRB10 knockdown on Th17 differentiation was quite limited. We also observed hyperphosphorylation of S6K1 in TSC1-deficient YFP + Treg cells ( Figure 7E ) and performed further knockdown of S6K1 expression in both WT and TSC1-deficient YFP + Treg cells by using the MSCV-based pLMP-mAmetrine retroviral vector to distinguish from the expression of YFP ( Figure 7F ). Our examination of the cytokine profile by a Bio-Plex multicytokine assay revealed a significant reduction of IL-1β and IL-17 secretion in culture supernatants of sorted TSC1-deficient YFP + mAmetrine + Treg cells ( Figure 7G ). These observations implicate a critical role for TSC1-mediated regulation of mTORC1/S6K1 signaling in IL-17 production in both conventional CD4 + T cells and Treg cells.
Additional Foxo3a ablation promotes Treg-to-Th17-like cell conversion. To understand the role of attenuated Foxo1/Foxo3a phosphorylation in regulating Treg cell plasticity in the absence of TSC1, we generated double-knockout mice lacking TSC1 and Foxo3a and bred them with the double-reporter mice (referred to herein as Foxp3 YFPCre R26 RFP Tsc1 f/f Foxo3a f/f ). We found that the population of RFP + YFP -(ex-Treg) T cells ( Figure 8A ) and the surface phenotype (data not shown) of TSC1/Foxo3a double-deficient Treg cells were similar to those observed in TSC1 single-deficient Treg cells under normal conditions. However, when stimulated with anti-CD3 and anti-CD28, TSC1/Foxo3a double deficiency induced a robust production of IL-17 in RFP + YFP + Treg cells ( Figure 8B, right panel) , and even greater amounts of effector cytokines were secreted in TSC1/ Foxo3a double-deficient RFP + YFP -(ex-Treg) T cells ( Figure 8B , left panel). We found that the increased IL-17 production in both TSC1-and TSC1/Foxo3a-deficient Treg cells was reduced by the treatment of mTOR inhibitor rapamycin ( Figure 8C ). These E, and F) or representative of (D and H) three independent experiments with two mice each. Error bars indicate the mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed, unpaired Student's t test. of (A, B, G, and H) or compiled from (D-F) two to five independent experiments. Error bars indicate the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by two-tailed, unpaired Student's t test.
which is opposite to the effect of TSC1 deletion in naive T cells that has been known to affect the survival and quiescence of naive T cells (14, 15) . Since regulation of the degree of metabolic demands and mTOR activity has been known to be a critical process for T cell fate determination (29) , this finding suggests that the distinct difference in the requirements for mTOR activity in the respective T cell subsets is important not only in directing T cell fate, but also in maintaining their homeostasis and modulating their immunological functions.
One interesting finding of the present study is that TSC1-deficient Foxp3 + Treg cells showed impaired suppressive activity and reduced Foxp3 expression only under inflammatory conditions. Furthermore, TSC1 deficiency selectively induced the conversion of Treg cells into Th17-like effector T cells. Several recent studies have shown that Treg cells lose Foxp3 expression and become "ex-Tregs" that acquire an effector memory phenotype and produce proinflammatory cytokines (19) (20) (21) (22) . However, the issue of Treg cell lineage commitment remains controversial (23, 24) . In our fate-mapping study involving cells, and the nuclear translocation of RORγt, respectively (30) . Further study of the regulatory mechanisms of S6K1 action and the role of other mTORC1 substrates, such as 4E-BP1 and GRB10 in Treg cells, is required to gain more insight into the link between TSC1/mTORC1 signaling and Th17/Treg balance.
Several recent studies have shown that mTORC2-mediated phosphorylation of downstream Foxo1 and Foxo3a inhibits Foxp3 expression (31) (32) (33) . However, mTORC2 inhibition by genetic deletion of Rictor is not sufficient for Treg cell generation when mTORC1 activity remains intact (6). Since we found that heightened mTORC1 activity in TSC1-deficient T cells downregulated mTORC2 activity by negative feedback, as assessed by reduced Foxo1/3a phosphorylation, we reasoned that this reduced mTORC2 activity may compromise the effect of augmented mTORC1 activity on Treg stability and function. Indeed, Foxo3a deletion in TSC1-deficient Treg cells largely accelerated the conversion of Treg cells into Th17-like effector T cells. And furthermore, rapamycin treatment blocked this reprogramming of TSC1/Foxo3a-deficient Treg cells, even though rapamycin has been known to enhance mTORC2 activity by inhibiting mTORC1 activity, which suggests that TSC1 has a dominant role in retaining the stability and functional ability of Treg cells by maintaining an appropriate balance between mTORC1 and mTORC2 activity.
In conclusion, our studies demonstrate that TSC1 acts as a key mediator in integrating the environmental cues and immunologsome point, this could have been due to an incomplete differentiation and commitment to become Treg cells, as opposed to a loss of Foxp3 expression by committed Treg cells. An increased acquisition of a Th17-like phenotype by TSC1-deficient Treg cells was also found in a competitive environment, although this conversion was greatly promoted under inflammatory conditions, which was probably provoked by the production of inflammatory cytokines such as IL-1 and IL-6. Furthermore, we found that aged Foxp3 YFPCre R26 RFP Tcs1 f/f mice exhibited dysregulated immune homeostasis along with an increase in ex-Treg (RFP + YFP -) fractions, which provides convincing evidence that ex-Treg generation is caused by TSC1 deficiency-induced reprogramming of Treg cells under physiological conditions and not simply by aberrant homeostatic expansion in lymphopenic hosts.
Previous studies have shown the importance of mTOR signaling in the regulation of Th cell differentiation (5-7). In our study, the enhanced Th17 responses were likely associated with mTORC1-dependent signal transduction to its downstream substrate S6K1, since in vivo knockdown of S6K1 rescued the hyperresponsiveness of both IL-17-producing effector T cells and Treg cells to a remarkable extent. Although the detailed mechanism of how S6K1 is involved in the regulation of T cell lineage-specific gene expression has been poorly understood, a recent study showed a key role for S6K1 and S6K2 in Th17 differentiation via the regulation of GFI1 expression, a negative regulator of Th17 Cytokine production was measured by Bio-Plex multicytokine assay. Data are representative of (A) or compiled from (B and C) three independent experiments. Error bars indicate the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by two-tailed, unpaired Student's t test.
